Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review.
<h4>Background</h4>Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Comorbidities are often reported in patients with COPD and may influence the cost of care. Yet, the extent by which comorbidities affect costs remains to be determined...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0123292 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839630388107935744 |
|---|---|
| author | Manuel B Huber Margarethe E Wacker Claus F Vogelmeier Reiner Leidl |
| author_facet | Manuel B Huber Margarethe E Wacker Claus F Vogelmeier Reiner Leidl |
| author_sort | Manuel B Huber |
| collection | DOAJ |
| description | <h4>Background</h4>Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Comorbidities are often reported in patients with COPD and may influence the cost of care. Yet, the extent by which comorbidities affect costs remains to be determined.<h4>Objectives</h4>To review, quantify and evaluate excess costs of comorbidities in COPD.<h4>Methods</h4>Using a systematic review approach, Pubmed and Embase were searched for studies analyzing excess costs of comorbidities in COPD. Resulting studies were evaluated according to study characteristics, comorbidity measurement and cost indicators. Mark-up factors were calculated for respective excess costs. Furthermore, a checklist of quality criteria was applied.<h4>Results</h4>Twelve studies were included. Nine evaluated comorbidity specific costs; three examined index-based results. Pneumonia, cardiovascular disease and diabetes were associated with the highest excess costs. The mark-up factors for respective excess costs ranged between 1.5 and 2.5 in the majority of cases. On average the factors constituted a doubling of respective costs in the comorbid case. The main cost driver, among all studies, was inpatient cost. Indirect costs were not accounted for by the majority of studies. Study heterogeneity was high.<h4>Conclusions</h4>The reviewed studies clearly show that comorbidities are associated with significant excess costs in COPD. The inclusion of comorbid costs and effects in future health economic evaluations of preventive or therapeutic COPD interventions seems highly advisable. |
| format | Article |
| id | doaj-art-dba9d612e0024881ac58c32f54a0adf3 |
| institution | Matheson Library |
| issn | 1932-6203 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-dba9d612e0024881ac58c32f54a0adf32025-07-14T05:31:49ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e012329210.1371/journal.pone.0123292Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review.Manuel B HuberMargarethe E WackerClaus F VogelmeierReiner Leidl<h4>Background</h4>Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Comorbidities are often reported in patients with COPD and may influence the cost of care. Yet, the extent by which comorbidities affect costs remains to be determined.<h4>Objectives</h4>To review, quantify and evaluate excess costs of comorbidities in COPD.<h4>Methods</h4>Using a systematic review approach, Pubmed and Embase were searched for studies analyzing excess costs of comorbidities in COPD. Resulting studies were evaluated according to study characteristics, comorbidity measurement and cost indicators. Mark-up factors were calculated for respective excess costs. Furthermore, a checklist of quality criteria was applied.<h4>Results</h4>Twelve studies were included. Nine evaluated comorbidity specific costs; three examined index-based results. Pneumonia, cardiovascular disease and diabetes were associated with the highest excess costs. The mark-up factors for respective excess costs ranged between 1.5 and 2.5 in the majority of cases. On average the factors constituted a doubling of respective costs in the comorbid case. The main cost driver, among all studies, was inpatient cost. Indirect costs were not accounted for by the majority of studies. Study heterogeneity was high.<h4>Conclusions</h4>The reviewed studies clearly show that comorbidities are associated with significant excess costs in COPD. The inclusion of comorbid costs and effects in future health economic evaluations of preventive or therapeutic COPD interventions seems highly advisable.https://doi.org/10.1371/journal.pone.0123292 |
| spellingShingle | Manuel B Huber Margarethe E Wacker Claus F Vogelmeier Reiner Leidl Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review. PLoS ONE |
| title | Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review. |
| title_full | Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review. |
| title_fullStr | Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review. |
| title_full_unstemmed | Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review. |
| title_short | Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review. |
| title_sort | excess costs of comorbidities in chronic obstructive pulmonary disease a systematic review |
| url | https://doi.org/10.1371/journal.pone.0123292 |
| work_keys_str_mv | AT manuelbhuber excesscostsofcomorbiditiesinchronicobstructivepulmonarydiseaseasystematicreview AT margaretheewacker excesscostsofcomorbiditiesinchronicobstructivepulmonarydiseaseasystematicreview AT clausfvogelmeier excesscostsofcomorbiditiesinchronicobstructivepulmonarydiseaseasystematicreview AT reinerleidl excesscostsofcomorbiditiesinchronicobstructivepulmonarydiseaseasystematicreview |